{"id":798834,"date":"2025-01-08T07:34:18","date_gmt":"2025-01-08T12:34:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-provides-corporate-update-and-highlights-key-upcoming-milestones\/"},"modified":"2025-01-08T07:34:18","modified_gmt":"2025-01-08T12:34:18","slug":"sensei-biotherapeutics-provides-corporate-update-and-highlights-key-upcoming-milestones","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-provides-corporate-update-and-highlights-key-upcoming-milestones\/","title":{"rendered":"Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones"},"content":{"rendered":"
\n

\n – Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 –<\/em>\n <\/p>\n

\n – Clinical data update expected in Q2 2025 – <\/em>\n <\/p>\n

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its lead program, solnerstotug (SNS-101) and upcoming milestones.<\/p>\n

\u201c2024 was a noteworthy year for Sensei and our pioneering lead program, solnerstotug. We demonstrated that solnerstotug can overcome the safety and pharmacological hurdles associated with first-generation antibodies targeting the immune checkpoint VISTA, positioning it as the first program in its class with potential to demonstrate clinically meaningful antitumor responses. Moreover, despite enrolling a predominantly \u2018cold\u2019 tumor patient population that was unlikely to respond to immunotherapy, solnerstotug demonstrated promising early signs of activity,\u201d said John Celebi, President and Chief Executive Officer. \u201cLooking ahead, 2025 is set to be a pivotal year as we seek to share our first significant efficacy data at optimal doses that include a \u2018hot\u2019 tumor patient population more likely to respond to immunotherapy that nonetheless has primary or acquired resistance to PD-1 inhibitors. With cash runway into the second quarter of 2026, we are positioned to advance solnerstotug through the completion of the Phase 1 portion of this study.\u201d<\/p>\n

\n Highlights and Milestones<\/strong>\n <\/p>\n

\n Solnerstotug (SNS-101)<\/u>\n <\/p>\n

Solnerstotug is a conditionally active antibody designed to selectively target the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation) within the tumor microenvironment. VISTA is implicated in numerous cancer indications and its expression correlates with low survival rates.<\/p>\n

Sensei is conducting a multi-center Phase 1\/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of solnerstotug (SNS-101) as both a monotherapy and in combination with Regeneron\u2019s PD-1 inhibitor Libtayo\u00ae (cemiplimab) in patients with advanced solid tumors. Key findings and updates as of January 1, 2025 include:<\/p>\n